PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING LUPUS NEPHRITIS AND BIOMARKER FOR LUPUS NEPHRITIS

• 1. 乌司他丁作为制备治疗系统性红斑狼疮药物的用途及其药物组合物 [P] . 中国专利： CN101954071B . 2013.09.25
• 2. 乌司他丁作为制备治疗系统性红斑狼疮药物的用途及其药物组合物 [P] . 中国专利： CN101954071A . 2011-01-26
• 3. Biomarkers of drug composition and lupus nephritis for treating or preventing lupus nephritis [P] . JP6964322B2 . 2021-11-10

  机译： 药物组合物和狼疮肾炎的生物标志物，用于治疗或预防狼疮性肾炎

• 4. Pharmaceutical composition comprising substituted benzenesulfonamide compounds for use in treating systemic lupus erythematosus, lupus nephritis or sjogren's syndrome [P] . IL226490A . 2017-05-29

  机译： 包含取代的苯磺酰胺化合物的药物组合物，用于治疗系统性红斑狼疮，狼疮肾炎或干燥综合征

• 5. PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING LUPUS NEPHRITIS COMPRISING SOLUBLE RAGE AS ACTIVE INGREDIENT [P] . 韩国专利： KR20130083861A . 2013-07-23

  机译： 预防和治疗狼疮性肾病的药物组合物，包括可溶性愤怒作为活性成分

• 1. A Case Report of Lupus Panniculitis in a Hemodialysis Patient with Lupus Nephritis [J] . Zhi Xiao, Yanyu Li 临床医学病理报告（英文） . 2021,第004期
• 2. Outcome of Leflunomide in the Treatment of Proliferative Lupus Nephritis Compared to Cyclophosphamide [J] . Shahida Mullah, Muhammad Rafiqul Alam, Shamim Ahmed, 生物科学与医学（英文） . 2021,第003期
• 3. Infectious Complications in Lupus Nephritis and Associated Factors: A Multicenter Study [J] . Mansour Mbengue, Myriam Mezouari, Seynabou Diagne, 肾脏病（英文） . 2021,第004期
• 4. Comparison of urinary parameters, biomarkers, and outcome of childhood systemic lupus erythematosus early onset-lupus nephritis [J] . Miguel Daniele Faria, Terreri Maria Teresa, Pereira Rosa Maria Rodrigues, Advances in Rheumatology . 2020,第a期
• 5. Serum miRNA-146a and miRNA-155 as Novel Biomarkers in Lupus Nephritis Activity with Systemic Lupus Erythematosus [J] . Nalgaa Abou-Elfattah Tawfik, Omnia Ahmed El-Dydamoni, Sara Younes Abozaid, American Journal of Biochemistry . 2019,第2期
• 6. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis [J] . Qi S., Chen Q., Xu D., Lupus . 2018,第10期
• 7. Comparing Mask R-CNN and U-Net architectures for robust automatic segmentation of immune cells in immunofluorescence images of Lupus Nephritis biopsies [C] . Madeleine S. Durkee, Rebecca Abraham, Junting Ai, Conference on Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues . 2021
• 8. What Are the Best Treatments for Proliferative Lupus Nephritis [D] . Tian, Yu. 2018
• 9. B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus [O] . Huidi Zhang, Xixi Huang, Lulu Ye, -1
• 10. A lupus nephritis kezelésének irányelvei, valamint aud mycofenolat mofetil hatékonyságának bemutatása intézetünk lupus nephritisesud betegeinek körében Clinical guideline for the treatment of lupus nephritis and single-centre results udof mycofenolate mofetil among patients with lupus nephritis in the National udInstitute of Rheumatology and Physiotherapy, Budapest [O] . Szabó Melinda Zsuzsanna, Kiss Emese 2016

• 1. Alport syndrome combined with lupus nephritis in a Chinese family:A case report [J] . Hui-Fang Liu ,Qing Li ,You-Qun Peng . 世界临床病例杂志 . 2021,第018期
• 2. Prognostic Aspects of Lupus Nephritis at Aristide Le Dantec University Hospital in Dakar [J] . Mbengue Mansour ,Faye Maria ,Cissé Mouhamadou Moustapha . 肾脏病（英文） . 2018,第4期
• 3. 系统性红斑狼疮(SLE)的表观遗传发病机制，早期生物学标记和治疗目标 [C] . . 第14次全国皮肤性病学术年会 . 2008
• 4. 系统性红斑狼疮与狼疮性肾炎的药物治疗进展 [A] . 张妍君 . 2018